Cargando…
Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study
BACKGROUND: Women using unopposed estrogens during menopause are at increased risk of ovarian cancer. It is uncertain whether oestrogen plus progestin therapy exerts similar effects. METHODS: We evaluated menopausal hormone use and incident ovarian cancer (n=426) in 92 601 post-menopausal women enro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461172/ https://www.ncbi.nlm.nih.gov/pubmed/22929888 http://dx.doi.org/10.1038/bjc.2012.397 |
_version_ | 1782245048841142272 |
---|---|
author | Trabert, B Wentzensen, N Yang, H P Sherman, M E Hollenbeck, A Danforth, K N Park, Y Brinton, L A |
author_facet | Trabert, B Wentzensen, N Yang, H P Sherman, M E Hollenbeck, A Danforth, K N Park, Y Brinton, L A |
author_sort | Trabert, B |
collection | PubMed |
description | BACKGROUND: Women using unopposed estrogens during menopause are at increased risk of ovarian cancer. It is uncertain whether oestrogen plus progestin therapy exerts similar effects. METHODS: We evaluated menopausal hormone use and incident ovarian cancer (n=426) in 92 601 post-menopausal women enrolled in the National Institutes of Health-AARP (NIH-AARP) Diet and Health Study. Participants were administered questionnaires in 1996–1997 and followed through 2006. Hazard rate ratios (RR) and 95% confidence intervals (CIs) were estimated using Cox regression. RESULTS: Increased risks were associated with long duration (10+ years) use of unopposed oestrogen (RR 2.15, 95% CI: 1.30–3.57 among women with a hysterectomy) and oestrogen plus progestin (RR 1.68, 95% CI: 1.13–2.49 among women with intact uteri) therapy. Similar risks were associated with progestins that were used sequentially (<15 days progestin per month) (RR 1.60, 95% CI: 1.10–2.33) or continuously (>25 days progestin per month) (RR 1.43, 95% CI: 1.032–2.01; P-value for heterogeneity=0.63). CONCLUSION: Our findings suggest that long duration use of both unopposed estrogens and oestrogen plus progestins are associated with increased risks of ovarian cancer, and that risk associated with oestrogen plus progestin use does not vary by regimen (sequential or continuous). |
format | Online Article Text |
id | pubmed-3461172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34611722013-09-25 Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study Trabert, B Wentzensen, N Yang, H P Sherman, M E Hollenbeck, A Danforth, K N Park, Y Brinton, L A Br J Cancer Epidemiology BACKGROUND: Women using unopposed estrogens during menopause are at increased risk of ovarian cancer. It is uncertain whether oestrogen plus progestin therapy exerts similar effects. METHODS: We evaluated menopausal hormone use and incident ovarian cancer (n=426) in 92 601 post-menopausal women enrolled in the National Institutes of Health-AARP (NIH-AARP) Diet and Health Study. Participants were administered questionnaires in 1996–1997 and followed through 2006. Hazard rate ratios (RR) and 95% confidence intervals (CIs) were estimated using Cox regression. RESULTS: Increased risks were associated with long duration (10+ years) use of unopposed oestrogen (RR 2.15, 95% CI: 1.30–3.57 among women with a hysterectomy) and oestrogen plus progestin (RR 1.68, 95% CI: 1.13–2.49 among women with intact uteri) therapy. Similar risks were associated with progestins that were used sequentially (<15 days progestin per month) (RR 1.60, 95% CI: 1.10–2.33) or continuously (>25 days progestin per month) (RR 1.43, 95% CI: 1.032–2.01; P-value for heterogeneity=0.63). CONCLUSION: Our findings suggest that long duration use of both unopposed estrogens and oestrogen plus progestins are associated with increased risks of ovarian cancer, and that risk associated with oestrogen plus progestin use does not vary by regimen (sequential or continuous). Nature Publishing Group 2012-09-25 2012-08-28 /pmc/articles/PMC3461172/ /pubmed/22929888 http://dx.doi.org/10.1038/bjc.2012.397 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Epidemiology Trabert, B Wentzensen, N Yang, H P Sherman, M E Hollenbeck, A Danforth, K N Park, Y Brinton, L A Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study |
title | Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study |
title_full | Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study |
title_fullStr | Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study |
title_full_unstemmed | Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study |
title_short | Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study |
title_sort | ovarian cancer and menopausal hormone therapy in the nih-aarp diet and health study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461172/ https://www.ncbi.nlm.nih.gov/pubmed/22929888 http://dx.doi.org/10.1038/bjc.2012.397 |
work_keys_str_mv | AT trabertb ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy AT wentzensenn ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy AT yanghp ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy AT shermanme ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy AT hollenbecka ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy AT danforthkn ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy AT parky ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy AT brintonla ovariancancerandmenopausalhormonetherapyinthenihaarpdietandhealthstudy |